Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NUVB vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANNX Captures Overall Composite Edge (38.6 SELL vs 61.0 BUY), While NUVB Leads 3–2 on Growth & Valuation Pillars

ANNX Overall Winner 6-Pillar Tally: NUVB 3 – 2 ANNX (1 Tie) Matrix Metrics: NUVB 6 – 2 ANNX

As of Nov 20, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (38.6/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus ANNX at $3.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ANNX 38.6/100 SELL), ANNX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -61.2% operating margin) and revenue trajectory (+0.0% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUVB vs ANNX
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87
ANNX NASDAQ Head-to-Head Winner
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.10
-9.09% 1D
Market Cap $650.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.67β · 66% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 25.0 Fund 50.0 Flow 71.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 30
RSI-14: 29.7 · SMA20: $3.89 · SMA50: $3.93

6-Pillar Scorecard Institutional Category Breakdown (NUVB 3 – 2 ANNX)

Columns: Metric · NUVB · ANNX
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x N/M
2. Growth & Scale NUVB
Revenue Growth (YoY) +242.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $202M N/A
Market Cap $1.3B $650.5M
3. Profitability & Quality ANNX
Gross Margin 85.8% N/A
Operating Margin -61.2% 0.0%
Net Profit Margin -67.4% 0.0%
Return on Equity (ROE) -49.1% -130.8%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$108M -$190M
Cash Flow Margin -53.6% N/A
Net Cash / Leverage $146M Net Debt (1.32x D/E) $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 65.2% (26th %ile) 178.0% (24th %ile)
Put/Call OI Skew 0.24x (Call-Skewed) 0.77x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUVB (6) vs ANNX (2)
Institutional Metric NUVB ANNX Criterion Row Edge
Market Capitalization
Scale
$1.3B $650.5M Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+242.6% +0.0% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.2% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
-67.4% 0.0% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-49.1% -130.8% Higher ROE NUVB
52-Week Range Position
Momentum
2% ($4–$10) 1% ($3–$7) Stronger Trend NUVB
Beta / 30D Volatility
Risk Regime
1.52β · 55% Vol 1.67β · 66% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
61.0 / 100 (BUY) 38.6 / 100 (SELL) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$202M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($146M Net Debt (1.32x D/E)) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +0.51 pp
NUVB: -19.15% · ANNX: -18.64%
3M Horizon ANNX +5.05 pp
NUVB: -43.79% · ANNX: -38.74%
6M Horizon NUVB +22.13 pp
NUVB: -19.49% · ANNX: -41.62%
1Y Horizon ANNX +23.2 pp
NUVB: -46.85% · ANNX: -23.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUVB vs ANNX. Trailing 12-month operating profitability (NUVB -61.2% vs ANNX 0.0%) and valuation multiples (NUVB N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NUVB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$202M
Gross Margin85.8%
Op. Margin-61.2%
ROE / Fwd P/E-49.1% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 178.0%
IV Percentile 24th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $650.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUVB vs ANNX Key Questions & Quantitative Answers

As of Nov 20, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (38.6/100 SELL vs. 61.0/100 BUY) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus ANNX at $3.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ANNX 38.6/100 SELL), ANNX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -61.2% operating margin) and revenue trajectory (+0.0% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NUVB generates $202M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, ANNX carries 178.0% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.67β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.